Terns PharmaceuticalsTERN
TERN
About: Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
Employees: 59
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
325% more call options, than puts
Call options by funds: $3.7M | Put options by funds: $869K
103% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 33
33% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]
7.26% more ownership
Funds ownership: 94.14% [Q3] → 101.4% (+7.26%) [Q4]
6% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 35
1% more funds holding
Funds holding: 155 [Q3] → 156 (+1) [Q4]
28% less capital invested
Capital invested by funds: $663M [Q3] → $477M (-$186M) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$20
578%
upside
Avg. target
$20
578%
upside
High target
$20
578%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
JMP Securities Silvan Tuerkcan 26% 1-year accuracy 14 / 53 met price target | 578%upside $20 | Market Outperform Reiterated | 21 Apr 2025 |
Financial journalist opinion
Based on 3 articles about TERN published over the past 30 days
Positive
Zacks Investment Research
3 weeks ago
Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals (TERN) Looks Ripe for a Turnaround
Terns Pharmaceuticals (TERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Positive
Zacks Investment Research
3 weeks ago
Down -31.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Terns Pharmaceuticals (TERN)
Terns Pharmaceuticals (TERN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Neutral
GlobeNewsWire
3 weeks ago
Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of April 1, 2025 an equity inducement award to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with Terns.
Positive
Zacks Investment Research
1 month ago
All You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to Buy
Terns Pharmaceuticals (TERN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
GlobeNewsWire
1 month ago
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 First patient enrolled in Phase 2 FALCON trial of TERN-601 for obesity with 12-week data expected 4Q25 Cash, cash equivalents and marketable securities of $358 million, expected to provide runway into 2028 FOSTER CITY, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided corporate updates.
Positive
The Motley Fool
1 month ago
This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street
Last year, Viking Therapeutics, a mid-cap biotech, made waves after it reported excellent phase 2 results for an investigational medicine for weight loss, the industry's hottest and perhaps fastest-growing therapeutic area. Analysts remain bullish on Viking, but another weight loss company boasts even more significant upside potential, judging by Wall Street's predictions: Terns Pharmaceuticals (TERN -3.86%).
Neutral
GlobeNewsWire
1 month ago
Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of February 24, 2025 an equity inducement award to Andrew Gengos, the Company's new chief financial officer, under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity award was approved by the Compensation Committee of the Company's Board of Directors and the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to Mr. Gengos' acceptance of employment with Terns.
Neutral
GlobeNewsWire
2 months ago
Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference
TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25
Neutral
GlobeNewsWire
2 months ago
Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer
Seasoned public company CFO with 25 years of leadership experience in biotech Seasoned public company CFO with 25 years of leadership experience in biotech
Neutral
GlobeNewsWire
2 months ago
Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors
Seasoned biotechnology CEO brings 25 years of strategic, operational and commercial expertise Seasoned biotechnology CEO brings 25 years of strategic, operational and commercial expertise
Charts implemented using Lightweight Charts™